ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. Public
  1. Public
  2. 国外雑誌論文

Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication

https://asahikawa-med.repo.nii.ac.jp/records/6012
https://asahikawa-med.repo.nii.ac.jp/records/6012
6825000d-88d8-4f57-ba3b-79a898fdd186
名前 / ファイル ライセンス アクション
7146.pdf 7146.pdf (969.1 kB)
Item type 学術雑誌論文 / Journal Article_02(1)
公開日 2018-12-06
タイトル
タイトル Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication
言語
言語 eng
資源タイプ
資源タイプ journal article
著者 田邊, 裕貴

× 田邊, 裕貴

田邊, 裕貴

ja-Kana タナベ, ヒロキ

Search repository
Yoshino, Keiichi

× Yoshino, Keiichi

Yoshino, Keiichi

Search repository
安藤, 勝祥

× 安藤, 勝祥

安藤, 勝祥

ja-Kana アンドウ, カツヨシ

Search repository
野村, 好紀

× 野村, 好紀

野村, 好紀

ja-Kana ノムラ, ヨシキ

Search repository
太田, 勝久

× 太田, 勝久

太田, 勝久

ja-Kana オオタ, カツヒサ

Search repository
佐藤, 貴一

× 佐藤, 貴一

佐藤, 貴一

ja-Kana サトウ, キイチ

Search repository
一石, 英一郎

× 一石, 英一郎

一石, 英一郎

ja-Kana イチイシ, エイイチロウ

Search repository
石塚, 彰映

× 石塚, 彰映

石塚, 彰映

ja-Kana イシヅカ, アキエイ

Search repository
大竹, 孝明

× 大竹, 孝明

大竹, 孝明

ja-Kana オオタケ, タカアキ

Search repository
高後, 裕

× 高後, 裕

高後, 裕

ja-Kana コウゴ, ユタカ

Search repository
藤谷, 幹浩

× 藤谷, 幹浩

藤谷, 幹浩

ja-Kana フジヤ, ミキヒロ

Search repository
奥村, 利勝

× 奥村, 利勝

奥村, 利勝

ja-Kana オクムラ, トシカツ

Search repository
著者 ローマ字
Tanabe, Hiroki
著者 ローマ字
著者 ローマ字
Ando, Katsuyoshi
著者 ローマ字
Nomura, Yoshiki
著者 ローマ字
Ohta, Katsuhisa
著者 ローマ字
Sato, Kiichi
著者 ローマ字
Ichiishi, Eiichiro
著者 ローマ字
Ishizuka, Akiei
著者 ローマ字
Otake, Takaaki
著者 ローマ字
Kohgo, Yutaka
著者 ローマ字
Fujiya, Mikihiro
著者 ローマ字
Okumura, Toshikatsu
書誌情報 Annals of Clinical Microbiology and Antimicrobials

号 17, p. 29, 発行日 2018-06-01
ISSN
収録物識別子タイプ ISSN
収録物識別子 1476-0711
DOI
関連タイプ isIdenticalTo
識別子タイプ DOI
関連識別子 10.1186/s12941-018-0281-x.
識別番号 その他
内容記述タイプ Other
内容記述 PMID:29950163
抄録
内容記述タイプ Abstract
内容記述 BACKGROUND:
\nAll Helicobacter pylori-infected patients are recommended for eradication with an appropriate regimen in each geographic area. The choice of the therapy is somewhat dependent on the antimicrobial susceptibility. The rate of clarithromycin resistance has been increasing and is associated with failure; thus, susceptibility testing is recommended before triple therapy with clarithromycin. However, antimicrobial susceptibility testing is not yet clinically available and an alternative newly developed acid inhibitor vonoprazan is used for triple therapy in Japan. The aim of this study was to determine whether vonoprazan-based triple therapy is plausible treatment in H. pylori eradication.
METHODS:
\nA retrospective observational study of H. pylori eradication was conducted in a single institute. The patients who requested antimicrobial susceptibility testing were treated with susceptibility-guided proton pump inhibitor-based triple therapy in International University of Health and Welfare Hospital from 2013 to 2016. Other patients were treated with empirical treatment with a proton pump inhibitor. From 2015 to 2016, vonoprazan-based triple treatment (vonoprazan, 20 mg; amoxicillin, 750 mg; and clarithromycin, 200 or 400 mg, b.i.d.) was conducted, and its effectiveness was compared with susceptibility-guided proton pump inhibitor-based triple therapy. We also investigated the improvement in eradication rate when antimicrobial susceptibility testing was performed, and compared the outcomes of vonoprazan-based and proton pump inhibitor-based empirical therapy.
RESULTS:
\nA total of 1355 patients who received first-line eradication treatment were enrolled in the present study. The eradication rates of the empirical proton pump inhibitor-based therapy and the vonoprazan-based therapy group in a per-protocol analysis were 86.3% (95% CI 83.8-88.8) and 97.4% (95% CI 95.7-99.1), respectively. In 212 patients who received antimicrobial susceptibility testing, the rate of clarithromycin resistant was 23.5% and the eradication rate in susceptibility-guided treatment was 95.7% (95% CI 92.9-98.4). The difference between susceptibility-guided and vonoprazan-based therapy was - 1.7% (95% CI - 4.9 to 1.5%), and the non-inferiority of vonoprazan-based triple therapy was confirmed.
CONCLUSIONS:
\nVonoprazan-based triple therapy was effective as susceptibility-guided triple therapy for H. pylori eradication. An empirical triple therapy with vonoprazan is preferable even in area with high rates of clarithromycin-resistance. Trial registration The study was retrospectively registered in University Hospital Medical Information Network (UMIN000032351).
注記
内容記述タイプ Other
注記 This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/)
資源タイプ
内容記述タイプ Other
資源タイプ text
著者版フラグ
出版タイプ VoR
フォーマット
内容記述タイプ Other
内容記述 application/pdf
ID(XooNIps)
29950163
閲覧数(XooNIps)
ダウンロード数(XooNIps)
544
戻る
0
views
See details
Views

Versions

Ver.1 2023-06-19 12:05:00.679169
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3